Click here to close now.




















Welcome!

News Feed Item

Neuromodulation Market - [Spinal Cord Stimulation (SCS), Vagus Nerve Stimulation (VNS), Gastric Electrical Stimulation (GES), Deep Brain Stimulation (DBS), Sacral Nerve Stimulation (SNS), & Transcranial Magnetic Stimulation (TMS)] - Forecasts to 2017

NEW YORK, Jan. 17, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Neuromodulation Market – [Spinal Cord Stimulation (SCS), Vagus Nerve Stimulation (VNS), Gastric Electrical Stimulation (GES), Deep Brain Stimulation (DBS), Sacral Nerve Stimulation (SNS), & Transcranial Magnetic Stimulation (TMS)] – Forecasts to 2017

http://www.reportlinker.com/p01083659/Neuromodulation-Market-–-[Spinal-Cord-Stimulation-SCS-Vagus-Nerve-Stimulation-VNS-Gastric-Electrical-Stimulation-GES-Deep-Brain-Stimulation-DBS-Sacral-Nerve-Stimulation-SNS--Transcranial-Magnetic-Stimulation-TMS]-–-Forecasts-to-2017 .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=NoCategory

Neuromodulation devices have emerged as one of the fastest growing segments of the medical device market due to high demand for minimally invasive and non–invasive treatment. With advancements in technology, neuromodulation is expected to become a promising therapeutic area and high growth industry in the next decade, as it offers symptomatic relief mainly from chronic pain, incontinence, heart failure, headache, depression, epilepsy, etc. The neuromodulation devices market includes deep brain stimulation, spinal cord stimulation, vagus nerve stimulation, sacral nerve stimulation and others external stimulation devices such as transcranial magnetic stimulation, and transcutaneous electrical nerve stimulation (TENS).

The neuromodulation technique acts directly upon nerves or the target area where the activity of nerves is altered due to biological responses produced by electrical stimulation or drug infusion. These devices include small electrodes that are attached to the brain, the spinal cord, or peripheral nerves. These precisely placed leads are connected by means of an extension cable to a pulse generator to generate electrical stimulation. Neuromodulation can have applications in any area of the body and can treat several diseases like chronic pain, epilepsy, psychiatric disorder, movement disorder, cardiovascular disorder, genitourinary and colorectal disorder, stroke and brain injury, and gastric disorder.

The main drivers for the neuromodulation market are the rising population of aged people and age-related diseases like Alzheimer's, epilepsy, spinal cord injury, and Parkinson's disease. According to the International Neuromodulation Society, about 40 million to 50 million patients worldwide suffer from epilepsy, and 1.5 million people currently (2012) suffer from Parkinson disease in the U.S. The large pool of patients that suffer from depression, stroke, anxiety disorders, lower back pain, urinary incontinence, and tremor offers the neuromodulation industry opportunities to grow in the next five years. The market for treatment of tinnitus, in particular, represents an emerging application of neuromodulation. According to the American Tinnitus Association, about 50 million people currently (2012) suffer from this disease in the U.S.

This report estimates the market for six major segments, namely, spinal cord stimulation, deep brain stimulation, sacral nerve stimulation, vagus nerve stimulation, gastric electrical stimulation, transcranial magnetic stimulation, and others. The report also estimates the market for different neuromodulation techniques as well as geographic analysis of each segment in North America, Europe, Asia-Pacific, and Rest of the World. As technologies develop and the number of trained physician increases, the likelihood of neuromodulation being seen as life-changing treatment will increase dramatically. It is estimated that the market for neuromodulation will be shared largely by deep brain stimulation and spinal cord stimulation.

The key players in the neuromodulation devices market are Medtronic, Inc. (U.S.), Cyberonics, Inc. (U.S.), Boston Scientific Corporation (U.S.), St. Jude Medical (U.S.), Enteromedics, Inc (U.S.), Neuropace, Inc (U.S.), Zynex, Inc (U.S.) and Neuronetics, Inc (U.S.). The emerging players in this market are Functional Neuromodulation, Ltd (U.S.), Microtransponder (U.S.), and Neurosigma, Inc (U.S.).

Scope of the Report

The research report categorizes the global neuromodulation devices market by procedure, technology, and application. These markets are broken down into segments and sub-segments, providing exhaustive value-volume analysis for 2010, 2011, and 2012 as well as forecast up to 2017. Each market is also analyzed by geography (North America, Europe, Asia-Pacific, and Rest of the World to provide in-depth information on the global scenario.

Global Neurostimulation Devices Market, by Procedure:

Internal Neurostimulation

Spinal Cord Stimulation (SCS)

Failed Back Surgery Syndrome

Chronic Pain

Ischemic Pain

Others

Deep Brain Stimulation (DBS)

Movement Disorders

Parkinson's Disease

Alzheimer's Disease

Dystonia

Tourette's Syndrome

Others

Chronic Pain

Depression

Post-Traumatic Coma

Sacral Nerve Stimulation (SNS)

Urine Incontinence

Fecal Incontinence

Vagus Nerve Stimulation (VNS)

Epilepsy disease

Heart Failure

Tinnitus

Others

Gastric Electrical Stimulation (GES)

Gastroparesis

Others

External Neurostimulation

Transcranial Magnetic Stimulation (TMS)

Depression

Tinnitus

Migraine

Stroke

Others

Transcutaneous Electrical Nerve Stimulation (TENS)

Global Neurostimulation Devices Market, by Geography

North AmericaEuropeAsia-PacificRest of the World

TABLE OF CONTENTS

1 INTRODUCTION 16

1.1 KEY TAKE-AWAYS 16

1.2 REPORT DESCRIPTION 16

1.3 MARKETS COVERED 18

1.4 RESEARCH METHODOLOGY 20

1.4.1 MARKET SIZE 20

1.4.2 MARKET SHARE 20

1.4.3 KEY DATA POINTS FROM SECONDARY SOURCES 20

1.4.4 KEY DATA POINTS FROM PRIMARY SOURCES 21

1.4.5 ASSUMPTIONS 21

1.5 STAKEHOLDERS 21

2 EXECUTIVE SUMMARY 22

3 MARKET OVERVIEW 25

3.1 INTRODUCTION 26

3.2 MARKET SEGMENTATION 27

3.3 MARKET DYNAMICS 29

3.3.1 DRIVERS 29

3.3.1.1 Increasing incidence of neurological disorders to spur market growth 29

3.3.1.2 Unprecedented global aging to fuel market growth 29

3.3.1.3 Strong product pipeline to propel the market 30

3.3.1.4 Expanded target applications and new indications are expected to stimulate growth of neuromodulation devices 30

3.3.1.5 Investments and funds – an impetus for market growth 31

3.4 RESTRAINTS 32

3.4.1.1 An unfavourable reimbursement scenario hinders market growth 32

3.4.1.2 Lack of trained professionals likely to hamper market growth 33

3.5 MARKET SHARE ANALYSIS 33

4 GLOBAL NEUROMODULATION MARKET (INTERNAL & EXTERNAL) 35

4.1 INTRODUCTION 36

4.2 INTERNAL STIMULATION 37

4.2.1 SPINAL CORD STIMULATION (SCS) MARKET 37

4.2.1.1 Major applications 39

4.2.1.1.1 Failed back surgery syndrome 40

4.2.1.1.2 Chronic pain 40

4.2.1.1.3 Ischemia 42

4.2.2 DEEP BRAIN STIMULATION (DBS) 42

4.2.2.1 Major applications 45

4.2.2.1.1 Parkinson's disease 46

4.2.2.1.2 Dystonia 47

4.2.2.1.3 Tremor 47

4.2.2.1.4 Alzheimer's 48

4.2.3 SACRAL NERVE STIMULATION (SNS) 48

4.2.3.1 Major applications 51

4.2.3.1.1 Urine incontinence 52

4.2.3.1.2 Fecal incontinence 53

4.2.4 VAGUS NERVE STIMULATION (VNS) 53

4.2.4.1 Major applications 56

4.2.4.1.1 Epilepsy 57

4.2.4.1.2 Others 58

4.2.5 GASTRIC ELECTRICAL STIMULATION (GES) 58

4.3 EXTERNAL STIMULATION 61

4.3.1 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) 61

4.3.2 TRANSCRANIAL MAGNETIC STIMULATION (TMS) 64

5 GEOGRAPHIC ANALYSIS 685.1 INTRODUCTION 695.2 NORTH AMERICA 725.3 EUROPE 805.4 ASIA 875.5 REST OF THE WORLD 976 COMPETITIVE LANDSCAPE 1066.1 INTRODUCTION 1066.2 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS, CONTRACTS & JOINT VENTURES 1086.3 NEW PRODUCT LAUNCH 1106.4 EXPANSION 1126.5 OTHER DEVELOPMENTS 1136.6 APPROVALS 1147 COMPANY PROFILES 122(Overview, Financials, Products & Services, Strategy, & Developments)*7.1 ANM ADAPTIVE NEUROMODULATION GMBH 1227.2 BIOCONTROL MEDICAL, LTD. 1257.3 BOSTON SCIENTIFIC CORPORATION 1287.4 CERBOMED GMBH 1367.5 CYBERONICS, INC. 1397.6 ENDOSTIM, INC. 1447.7 ENTEROMEDICS, INC. 1477.8 THE MAGSTIM COMPANY LIMITED 1507.9 MEDTRONIC, INC. 1537.10 NEURONETICS, INC. 1597.11 NEUROPACE, INC. 1627.12 NEUROSIGMA, INC. 1647.13 NEVRO CORPORATION 1677.14 RS MEDICAL 1697.15 SPINAL MODULATION, INC. 1727.16 ST. JUDE MEDICAL 1747.17 SYNAPSE BIOMEDICAL, INC. 1827.18 UROPLASTY, INC. 1847.19 ZYNEX, INC. 188*Details on financials, product & services, strategy, and developments might not be captured in case of unlisted companies.

LIST OF TABLES

TABLE 1 GLOBAL NEUROMODULATION MARKET, BY PROCEDURE,2010 – 2017 ($MILLION) 23TABLE 2 GLOBAL NEUROMODULATION MARKET, BY MODALITY,2010 – 2017 ($MILLION) 23TABLE 3 SPINAL CORD STIMULATION MARKET, BY GEOGRAPHY,2010 – 2017 ($MILLION) 38TABLE 4 SPINAL CORD STIMULATION MARKET VOLUME, BY GEOGRAPHY,2010 – 2017 (NO OF UNITS) 39TABLE 5 GLOBAL SPINAL CORD STIMULATION MARKET, BY APPLICATION,2010 – 2017 ($MILLION) 41TABLE 6 DEEP BRAIN STIMULATION MARKET, BY GEOGRAPHY,2010 – 2017 ($MILLION) 44TABLE 7 DEEP BRAIN STIMULATION MARKET VOLUME, BY GEOGRAPHY,2010-2017 (NO OF UNITS) 45TABLE 8 GLOBAL DEEP BRAIN STIMULATION MARKET, BY APPLICATION,2010 – 2017 ($MILLION) 46TABLE 9 SACRAL NERVE STIMULATION MARKET, BY GEOGRAPHY,2010 – 2017 ($MILLION) 50TABLE 10 SACRAL NERVE STIMULATION MARKET VOLUME, BY GEOGRAPHY,2010 – 2017 (NO OF UNITS) 51TABLE 11 GLOBAL SACRAL NERVE STIMULATION MARKET, BY APPLICATION,2010 – 2017 ($MILLION) 52TABLE 12 VAGUS NERVE STIMULATION MARKET, BY GEOGRAPHY,2010 – 2017 ($MILLION) 55TABLE 13 VAGUS NERVE STIMULATION MARKET VOLUME, BY GEOGRAPHY,2010 – 2017 (NO OF UNITS) 56TABLE 14 GLOBAL VAGUS NERVE STIMULATION MARKET, BY APPLICATION,2010 – 2017 ($MILLION) 57TABLE 15 GASTRIC ELECTRICAL STIMULATION MARKET, BY GEOGRAPHY,2010 – 2017 ($MILLION) 59TABLE 16 GASTRIC ELECTRICAL STIMULATION MARKET VOLUME,BY GEOGRAPHY, 2010 – 2017 (NO OF UNITS) 60TABLE 17 GLOBAL GASTRIC ELECTRICAL STIMULATION MARKET,BY APPLICATION, 2010-2017 ($MILLION) 61TABLE 18 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET,BY GEOGRAPHY, 2010 – 2017($MILLION) 63TABLE 19 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET VOLUME, BY GEOGRAPHY, 2010 – 2017 (NO OF UNITS) 64TABLE 20 TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 65TABLE 21 TRANSCRANIAL MAGNETIC STIMULATION MARKET VOLUME,BY GEOGRAPHY, 2010 – 2017 (NO OF UNITS) 66TABLE 22 GLOBAL TRANSCRANIAL MAGNETIC STIMULATION MARKET,BY APPLICATION, 2010 – 2017 ($MILLION) 67TABLE 23 NEUROMODULATION DEVICES MARKET, BY GEOGRAPHY,2010 – 2017 ($MILLION) 69TABLE 24 EXTERNAL NEUROMODULATION DEVICES MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 70TABLE 25 INTERNAL NEUROMODULATION DEVICES MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 71TABLE 26 GLOBAL EXTERNAL NEUROMODULATION MARKET, BY MODALITY,2010 – 2017 ($MILLION) 71TABLE 27 GLOBAL EXTERNAL NEUROMODULATION DEVICES MARKET VOLUME,BY MODALITY, 2010 – 2017 (NO OF UNITS) 72TABLE 28 NORTH AMERICA: NEUROMODULATION DEVICES MARKET,BY PROCEDURE, 2010 – 2017 ($MILLION) 73TABLE 29 NORTH AMERICA: INTERNAL NEUROMODULATION DEVICES MARKET, BY MODALITY, 2010 – 2017 ($MILLION) 74TABLE 30 NORTH AMERICA: INTERNAL NEUROMODULATION DEVICES MARKET VOLUME, BY MODALITY, 2010 – 2017 (NO. OF UNITS) 75TABLE 31 NORTH AMERICA: EXTERNAL NEUROMODULATION DEVICES MARKET, BY MODALITY, 2010 – 2017 ($MILLION) 75TABLE 32 NORTH AMERICA: EXTERNAL NEUROMODULATION DEVICES MARKET VOLUME, BY MODALITY, 2010 – 2017 (NO. OF UNITS) 76TABLE 33 NORTH AMERICA: SPINAL CORD STIMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 76TABLE 34 NORTH AMERICA: DEEP BRAIN STIMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 77TABLE 35 NORTH AMERICA: SACRAL NERVE STIMULATION, BY COUNTRY,2010 – 2017 ($MILLION) 77TABLE 36 NORTH AMERICA: VAGUS NERVE STIMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 78TABLE 37 NORTH AMERICA: GASTRIC ELECTRICAL STIMULATION MARKET,BY COUNTRY, 2010 – 2017 ($MILLION) 78TABLE 38 NORTH AMERICA: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 79TABLE 39 NORTH AMERICA: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 79TABLE 40 EUROPE: NEUROMODULATION DEVICES MARKET, BY PROCEDURE,2010 – 2017 ($MILLION) 81TABLE 41 EUROPE: INTERNAL NEUROMODULATION DEVICES MARKET,BY MODALITY, 2010 – 2017 ($MILLION) 81TABLE 42 EUROPE: INTERNAL NEUROMODULATION DEVICES MARKET VOLUME, BY MODALITY, 2010 – 2017 (NO. OF UNITS) 82TABLE 43 EUROPE: EXTERNAL NEUROMODULATION DEVICES MARKET,BY MODALITY, 2010 – 2017 ($MILLION) 83TABLE 44 EUROPE: EXTERNAL NEUROMODULATION DEVICES MARKET VOLUME, BY MODALITY, 2010 – 2017 (NO. OF UNITS) 83TABLE 45 EUROPE: SPINAL CORD STIMULATION MARKET, BY REGION,2010 – 2017 ($MILLION) 84TABLE 46 EUROPE: DEEP BRAIN STIMULATION MARKET, BY REGION,2010 – 2017 ($MILLION) 84TABLE 47 EUROPE: SACRAL NERVE STIMULATION, BY REGION,2010 – 2017 ($MILLION) 85TABLE 48 EUROPE: VAGUS NERVE STIMULATION MARKET, BY REGION,2010 – 2017 ($MILLION) 85TABLE 49 EUROPE: GASTRIC ELECTRICAL STIMULATION MARKET, BY REGION, 2010 – 2017 ($MILLION) 86TABLE 50 EUROPE: TRANSCRANIAL MAGNETIC STIMULATION MARKET,BY REGION, 2010 – 2017 ($MILLION) 86TABLE 51 EUROPE: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY REGION, 2010 – 2017 ($MILLION) 87TABLE 52 ASIA: NEUROMODULATION DEVICES MARKET, BY PROCEDURE,2010 – 2017 ($MILLION) 88TABLE 53 ASIA: INTERNAL NEUROMODULATION DEVICES MARKET, BY MODALITY, 2010 – 2017 ($MILLION) 89TABLE 54 ASIA: INTERNAL NEUROMODULATION DEVICES MARKET VOLUME,BY MODALITY, 2010 – 2017 (NO. OF UNITS) 90TABLE 55 ASIA: EXTERNAL NEUROMODULATION DEVICES MARKET,BY MODALITY, 2010 – 2017 ($MILLION) 90TABLE 56 ASIA: EXTERNAL NEUROMODULATION DEVICES MARKET VOLUME,BY MODALITY, 2010 – 2017 (NO. OF UNITS) 91TABLE 57 ASIA: SPINAL CORD STIMULATION MARKET, BY COUNTRY,2010 – 2017 ($MILLION) 92TABLE 58 ASIA: DEEP BRAIN STIMULATION MARKET, BY COUNTRY,2010 – 2017 ($MILLION) 93TABLE 59 ASIA: SACRAL NERVE STIMULATION, BY COUNTRY,2010 – 2017 ($MILLION) 94TABLE 60 ASIA: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 95TABLE 61 ASIA: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 96TABLE 62 ROW: NEUROMODULATION DEVICES MARKET, BY PROCEDURE,2010 – 2017 ($MILLION) 97TABLE 63 ROW: INTERNAL NEUROMODULATION DEVICES MARKET, BY MODALITY, 2010 – 2017 ($MILLION) 98TABLE 64 ROW: INTERNAL NEUROMODULATION DEVICES MARKET VOLUME,BY MODALITY, 2010 – 2017 (NO. OF UNITS) 99TABLE 65 ROW: EXTERNAL NEUROMODULATION DEVICES MARKET,BY MODALITY, 2010 – 2017 ($MILLION) 99TABLE 66 ROW: EXTERNAL NEUROMODULATION DEVICES MARKET VOLUME,BY MODALITY, 2010 – 2017 (NO. OF UNITS) 100TABLE 67 ROW: SPINAL CORD STIMULATION MARKET, BY REGION,2010 – 2017 ($MILLION) 100TABLE 68 ROW: DEEP BRAIN STIMULATION MARKET, BY REGION,2010 – 2017 ($MILLION) 101TABLE 69 ROW: SACRAL NERVE STIMULATION, BY REGION,2010 – 2017 ($MILLION) 102TABLE 70 ROW: VAGUS NERVE STIMULATION MARKET, BY REGION,2010 – 2017 ($MILLION) 102TABLE 71 ROW: GASTRIC ELECTRICAL STIMULATION MARKET, BY REGION,2010 – 2017 ($MILLION) 103TABLE 72 ROW: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY REGION, 2010 – 2017 ($MILLION) 104TABLE 73 ROW: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY REGION, 2010 – 2017 ($MILLION) 104TABLE 74 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS, CONTRACTS & JOINT VENTURES, 2010 – 2012 108TABLE 75 NEW PRODUCT LAUNCH, 2010 – 2012 110TABLE 76 EXPANSION, 2010 – 2012 112TABLE 77 OTHER DEVELOPMENTS, 2010 – 2012 113TABLE 78 APPROVALS, 2010 – 2012 114TABLE 79 BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE AND R&D EXPENDITURE, 2009 – 2011 ($MILLION) 129TABLE 80 BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION) 129TABLE 81 BOSTON SCIENTIFIC: TOTAL REVENUE, BY GEOGRAPHY,2009 – 2011 ($MILLION) 130TABLE 82 CYBERONICS, INC.: TOTAL REVENUE AND R&D EXPENDITURE,2009 – 2011 ($MILLION) 140TABLE 83 CYBERONICS, INC.: TOTAL REVENUE, BY GEOGRAPHY,2009 – 2011 ($MILLION) 140TABLE 84 MEDTRONIC, INC.: TOTAL REVENUE AND R&D EXPENDITURE,2009 – 2011 ($MILLION) 154TABLE 85 MEDTRONIC, INC: TOTAL REVENUE, BY SEGMENTS,2009 – 2011 ($MILLION) 154TABLE 86 MEDTRONIC, INC.: TOTAL REVENUE, BY GEOGRAPHY,2009 – 2011 ($MILLION) 155TABLE 87 ST. JUDE MEDICAL, INC: TOTAL REVENUE AND R&D EXPENDITURE, 2009 – 2011 ($MILLION) 175TABLE 88 ST. JUDE MEDICAL, INC: TOTAL REVENUE, BY SEGMENTS,2009 – 2011 ($MILLION) 175TABLE 89 ST. JUDE MEDICAL, INC: TOTAL REVENUE, BY GEOGRAPHY,2009 – 2011 ($MILLION) 176TABLE 90 UROPLASTY, INC.: TOTAL REVENUE AND R&D EXPENDITURE,2010-2012 ($MILLION) 185TABLE 91 UROPLASTY, INC.: TOTAL REVENUE, BY GEOGRAPHY,2010 – 2012 ($MILLION) 185TABLE 92 ZYNEX, INC.: TOTAL REVENUE AND R&D EXPENDITURE,2009 – 2011 ($MILLION) 189TABLE 93 ZYNEX, INC.: TOTAL REVENUE, BY SEGMENTS,2009 – 2011 ($MILLION) 189

LIST OF FIGURES

FIGURE 1 NEUROMODULATION MARKET SEGMENTATION 28FIGURE 2 MARKET DYNAMICS 32FIGURE 3 NEUROMODULATION MARKET SHARE ANALYSIS, BY REVENUE, 2011 34FIGURE 4 KEY GROWTH STRATEGIES, 2010 – 2012 107

To order this report: Neuromodulation Market – [Spinal Cord Stimulation (SCS), Vagus Nerve Stimulation (VNS), Gastric Electrical Stimulation (GES), Deep Brain Stimulation (DBS), Sacral Nerve Stimulation (SNS), & Transcranial Magnetic Stimulation (TMS)] – Forecasts to 2017

__________________________
Contact Nicolas: [email protected]
US: (805)-652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that HPM Networks will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. For 20 years, HPM Networks has been integrating technology solutions that solve complex business challenges. HPM Networks has designed solutions for both SMB and enterprise customers throughout the San Francisco Bay Area.
For IoT to grow as quickly as analyst firms’ project, a lot is going to fall on developers to quickly bring applications to market. But the lack of a standard development platform threatens to slow growth and make application development more time consuming and costly, much like we’ve seen in the mobile space. In his session at @ThingsExpo, Mike Weiner, Product Manager of the Omega DevCloud with KORE Telematics Inc., discussed the evolving requirements for developers as IoT matures and conducte...
The Software Defined Data Center (SDDC), which enables organizations to seamlessly run in a hybrid cloud model (public + private cloud), is here to stay. IDC estimates that the software-defined networking market will be valued at $3.7 billion by 2016. Security is a key component and benefit of the SDDC, and offers an opportunity to build security 'from the ground up' and weave it into the environment from day one. In his session at 16th Cloud Expo, Reuven Harrison, CTO and Co-Founder of Tufin,...
With SaaS use rampant across organizations, how can IT departments track company data and maintain security? More and more departments are commissioning their own solutions and bypassing IT. A cloud environment is amorphous and powerful, allowing you to set up solutions for all of your user needs: document sharing and collaboration, mobile access, e-mail, even industry-specific applications. In his session at 16th Cloud Expo, Shawn Mills, President and a founder of Green House Data, discussed h...
Mobile, social, Big Data, and cloud have fundamentally changed the way we live. “Anytime, anywhere” access to data and information is no longer a luxury; it’s a requirement, in both our personal and professional lives. For IT organizations, this means pressure has never been greater to deliver meaningful services to the business and customers.
Container technology is sending shock waves through the world of cloud computing. Heralded as the 'next big thing,' containers provide software owners a consistent way to package their software and dependencies while infrastructure operators benefit from a standard way to deploy and run them. Containers present new challenges for tracking usage due to their dynamic nature. They can also be deployed to bare metal, virtual machines and various cloud platforms. How do software owners track the usag...
The Internet of Everything (IoE) brings together people, process, data and things to make networked connections more relevant and valuable than ever before – transforming information into knowledge and knowledge into wisdom. IoE creates new capabilities, richer experiences, and unprecedented opportunities to improve business and government operations, decision making and mission support capabilities.
Chuck Piluso presented a study of cloud adoption trends and the power and flexibility of IBM Power and Pureflex cloud solutions. Prior to Secure Infrastructure and Services, Mr. Piluso founded North American Telecommunication Corporation, a facilities-based Competitive Local Exchange Carrier licensed by the Public Service Commission in 10 states, serving as the company's chairman and president from 1997 to 2000. Between 1990 and 1997, Mr. Piluso served as chairman & founder of International Te...
There are many considerations when moving applications from on-premise to cloud. It is critical to understand the benefits and also challenges of this migration. A successful migration will result in lower Total Cost of Ownership, yet offer the same or higher level of robustness. In his session at 15th Cloud Expo, Michael Meiner, an Engineering Director at Oracle, Corporation, analyzed a range of cloud offerings (IaaS, PaaS, SaaS) and discussed the benefits/challenges of migrating to each offe...
Puppet Labs has announced the next major update to its flagship product: Puppet Enterprise 2015.2. This release includes new features providing DevOps teams with clarity, simplicity and additional management capabilities, including an all-new user interface, an interactive graph for visualizing infrastructure code, a new unified agent and broader infrastructure support.
SYS-CON Events announced today that MobiDev, a software development company, will exhibit at the 17th International Cloud Expo®, which will take place November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. MobiDev is a software development company with representative offices in Atlanta (US), Sheffield (UK) and Würzburg (Germany); and development centers in Ukraine. Since 2009 it has grown from a small group of passionate engineers and business managers to a full-scale mobi...
One of the hottest areas in cloud right now is DRaaS and related offerings. In his session at 16th Cloud Expo, Dale Levesque, Disaster Recovery Product Manager with Windstream's Cloud and Data Center Marketing team, will discuss the benefits of the cloud model, which far outweigh the traditional approach, and how enterprises need to ensure that their needs are properly being met.
Learn how to solve the problem of keeping files in sync between multiple Docker containers. In his session at 16th Cloud Expo, Aaron Brongersma, Senior Infrastructure Engineer at Modulus, discussed using rsync, GlusterFS, EBS and Bit Torrent Sync. He broke down the tools that are needed to help create a seamless user experience. In the end, can we have an environment where we can easily move Docker containers, servers, and volumes without impacting our applications? He shared his results so yo...
Palerra, the cloud security automation company, announced enhanced support for Amazon AWS, allowing IT security and DevOps teams to automate activity and configuration monitoring, anomaly detection, and orchestrated remediation, thereby meeting compliance mandates within complex infrastructure deployments. "Monitoring and threat detection for AWS is a non-trivial task. While Amazon's flexible environment facilitates successful DevOps implementations, it adds another layer, which can become a ...
In a recent research, analyst firm IDC found that the average cost of a critical application failure is $500,000 to $1 million per hour and the average total cost of unplanned application downtime is $1.25 billion to $2.5 billion per year for Fortune 1000 companies. In addition to the findings on the cost of the downtime, the research also highlighted best practices for development, testing, application support, infrastructure, and operations teams.